Table 4.
Correlation between drug% at 240 mins in in vitro lipolysis system and in vivo Fr
| Drug content at 240 mins in lipolytic system (%) | Fr (%) | |||
|---|---|---|---|---|
| Aqueous phase | Lipid phase | Pellet phase | ||
| GRI-MCT-SNEDDS | 71.08±0.59 | — | 18.72±0.15 | 195.54 |
| GRI-LCT-SNEDDS | 85.66±2.09* | 12.83±0.43 | 12.07±2.07 | 166.88 |
| CIN-MCT-SNEDDS | 52.95±2.14 | 27.78±2.79 | 25.13±2.82 | 1529.41 |
| CIN-LCT-SNEDDS | 26.24±4.02* | 58.24±0.44* | 5.52±4.70 | 2162.98 |
Notes: *compared with MCT-SNEDDS, P<0.05.
Abbreviations: drug%, drug distribution percentage content; GRI, griseofulvin; CIN, cinnarizine; SNEDDS, self-nanoemulsifying drug delivery system; MCT, medium-chain triglycerides; LCT, long-chain triglycerides; Fr, relative oral bioavailability.